当前位置: 首页 >> 检索结果
62. The promise and compromise of the WHO Pandemic Agreement for spillover prevention and One Health.
作者: Alexandra Finch.;Neil M Vora.;Latiffah Hassan.;Chris Walzer.;Raina K Plowright.;Robyn Alders.;Chyna Yong Suit-B.;John H Amuasi.;Moses Mulumba.;Ted Loch-Temzelides.;Sergio Guerrero-Sanchez.;Lawrence O Gostin.
来源: Lancet. 2025年 64. Pancreatic cancer.
作者: Thomas F Stoop.;Ammar A Javed.;Atsushi Oba.;Bas Groot Koerkamp.;Thomas Seufferlein.;Johanna W Wilmink.;Marc G Besselink.
来源: Lancet. 2025年405卷10485期1182-1202页
Pancreatic cancer is frequently a lethal disease with an aggressive tumour biology often presenting with non-specific symptoms. Median survival is approximately 4 months with a 5-year survival of 13%. Surveillance is recommended in individuals with familial pancreatic cancer, specific mutations, and high-risk intraductal papillary mucinous neoplasm, as they are at high risk of developing pancreatic cancer. Chemotherapy combined with surgical resection remains the cornerstone of treatment. However, only a small subset of patients are candidates for surgery. Multi-agent chemotherapy has improved survival in the palliative setting for patients with metastatic disease, as (neo)adjuvant and induction therapy have in patients with borderline resectable and locally advanced pancreatic. Given that pancreatic cancer is predicted to become the second leading cause of cancer-related death by 2030, novel therapies are urgently needed.
79. SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial.
作者: Christian Juhl Terkelsen.;Philip Freeman.;Jordi Sanchez Dahl.;Troels Thim.;Bjarne Linde Nørgaard.;Nils Sofus Borg Mogensen.;Mariann Tang.;Ashkan Eftekhari.;Jonas Agerlund Povlsen.;Steen Hvitfeldt Poulsen.;Lars Pedersen.;Jakob Hjort.;Julia Ellert.;Evald Høj Christiansen.;Henrik Toft Sørensen.;Henrik Nissen.
来源: Lancet. 2025年405卷10487期1362-1372页
Transcatheter aortic valve implantation (TAVI) is a guideline-directed treatment for severe aortic stenosis and degenerated aortic bioprostheses. When new transcatheter heart valve (THV) platforms for TAVI are launched, they should be compared with best-in-practice contemporary THVs for their short-term and long-term performance. The COMPARE-TAVI 1 trial was designed to provide a head-to-head comparison of the SAPIEN 3 or SAPIEN 3 Ultra THVs and the Myval or Myval Octacor THVs.
80. The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma.
作者: Sarah Zaman.;Jason H Wasfy.;Vikas Kapil.;Boback Ziaeian.;William A Parsonage.;Sira Sriswasdi.;Timothy J A Chico.;Davide Capodanno.;Róisín Colleran.;Nadia R Sutton.;Lei Song.;Nicole Karam.;Reecha Sofat.;Chiara Fraccaro.;Daniel Chamié.;Mirvat Alasnag.;Takayuki Warisawa.;Nieves Gonzalo.;Walid Jomaa.;Shamir R Mehta.;Elizabeth E S Cook.;Johan Sundström.;Stephen J Nicholls.;Leslee J Shaw.;Manesh R Patel.;Rasha K Al-Lamee.
来源: Lancet. 2025年405卷10486期1264-1312页 |